No one would argue that generalist LLMs aren’t incredible tools. But sometimes, you just need an expert. Here’s why the future of AI will be specialized.
Kyverna Therapeutics leads CAR-T therapy for autoimmune diseases, with KYV-101 showing unprecedented efficacy in SPS and MG registrational trials. KYTX's SPS trial achieved 81% clinically meaningful ...
New! Sign up for our free email newsletter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results